Literature DB >> 21956712

Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.

Apollina Goel1, Douglas R Spitz, George J Weiner.   

Abstract

Developing novel combined-modality therapeutic approaches based on understanding of the involvement of redox biology in apoptosis of malignant cells is a promising approach for improving clinical responses in B-cell lymphoma and multiple myeloma. Therapeutic modalities that generate reactive oxygen species (i.e., radiation, photodynamic therapy, and specific chemotherapeutic drugs) have been shown to be selectively cytotoxic to malignant B-cells. In this review, we will discuss agents that induce apoptosis in B-cell tumors by oxidative stress. Subsequently, a novel biochemical rationale (based on fundamental differences in cancer vs. normal cell oxidative metabolism) for combining oxidative stressors with radiotherapy and chemotherapy, that may lead to designing of more effective treatment strategies for B-cell malignancies, will be discussed. Besides providing potential curative benefit, such novel therapies could also selectively target and inhibit the emergence of drug-resistance in tumor cells, which is a major determinant of treatment failure in many B-cell malignancies.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21956712      PMCID: PMC3374635          DOI: 10.1002/jcb.23387

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  76 in total

Review 1.  Kinases as drug discovery targets in hematologic malignancies.

Authors:  A L Hannah
Journal:  Curr Mol Med       Date:  2005-11       Impact factor: 2.222

Review 2.  Redox signaling in cancer biology.

Authors:  David Gius; Douglas R Spitz
Journal:  Antioxid Redox Signal       Date:  2006 Jul-Aug       Impact factor: 8.401

3.  A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.

Authors:  Margaret E Tome; David B F Johnson; Lisa M Rimsza; Robin A Roberts; Thomas M Grogan; Thomas P Miller; Larry W Oberley; Margaret M Briehl
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

4.  Manganese superoxide dismutase: a hepatic acute phase protein regulated by interleukin-6 and glucocorticoids.

Authors:  W C Dougall; H S Nick
Journal:  Endocrinology       Date:  1991-11       Impact factor: 4.736

5.  Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.

Authors:  Apollina Goel; Angela Dispenzieri; Susan M Geyer; Suzanne Greiner; Kah-Whye Peng; Stephen J Russell
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

6.  Production of large amounts of hydrogen peroxide by human tumor cells.

Authors:  T P Szatrowski; C F Nathan
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

7.  Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma.

Authors:  T Zima; I Spicka; S Stípek; J Crkovská; J Pláteník; M Merta; V Tesar
Journal:  Neoplasma       Date:  1996       Impact factor: 2.575

8.  Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma.

Authors:  Sophia S Wang; Scott Davis; James R Cerhan; Patricia Hartge; Richard K Severson; Wendy Cozen; Qing Lan; Robert Welch; Stephen J Chanock; Nathaniel Rothman
Journal:  Carcinogenesis       Date:  2006-03-16       Impact factor: 4.944

Review 9.  Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.

Authors:  John P Leonard; Richard R Furman; Morton Coleman
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

10.  Induction of Mn-superoxide dismutase by tumor necrosis factor, interleukin-1 and interleukin-6 in human hepatoma cells.

Authors:  M Ono; H Kohda; T Kawaguchi; M Ohhira; C Sekiya; M Namiki; A Takeyasu; N Taniguchi
Journal:  Biochem Biophys Res Commun       Date:  1992-02-14       Impact factor: 3.575

View more
  14 in total

1.  Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.

Authors:  Huixing Zhou; Yuan Jian; Yun Leng; Nian Liu; Ying Tian; Guorong Wang; Wen Gao; Guangzhong Yang; Wenming Chen
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

2.  Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.

Authors:  Charles O Brown; Jeanine Schibler; Matthew P Fitzgerald; Neeraj Singh; Kelley Salem; Fenghuang Zhan; Apollina Goel
Journal:  Leuk Res       Date:  2013-03-26       Impact factor: 3.156

3.  Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.

Authors:  Kelley Salem; Charles O Brown; Jeanine Schibler; Apollina Goel
Journal:  Exp Hematol       Date:  2012-10-11       Impact factor: 3.084

Review 4.  Oxidative stress and proteasome inhibitors in multiple myeloma.

Authors:  Brittany C Lipchick; Emily E Fink; Mikhail A Nikiforov
Journal:  Pharmacol Res       Date:  2016-01-29       Impact factor: 7.658

5.  Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase.

Authors:  Charles O Brown; Kelley Salem; Brett A Wagner; Soumen Bera; Neeraj Singh; Ajit Tiwari; Amit Choudhury; Garry R Buettner; Apollina Goel
Journal:  Biochem J       Date:  2012-06-15       Impact factor: 3.857

6.  Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.

Authors:  Wafa Hassen; Alboukadel Kassambara; Thierry Reme; Surinder Sahota; Anja Seckinger; Laure Vincent; Guillaume Cartron; Jérôme Moreaux; Dirk Hose; Bernard Klein
Journal:  Oncotarget       Date:  2015-03-20

Review 7.  Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death.

Authors:  Mélody Caillot; Hassan Dakik; Frédéric Mazurier; Brigitte Sola
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

8.  A novel model of chronic wounds: importance of redox imbalance and biofilm-forming bacteria for establishment of chronicity.

Authors:  Sandeep Dhall; Danh Do; Monika Garcia; Dayanjan Shanaka Wijesinghe; Angela Brandon; Jane Kim; Antonio Sanchez; Julia Lyubovitsky; Sean Gallagher; Eugene A Nothnagel; Charles E Chalfant; Rakesh P Patel; Neal Schiller; Manuela Martins-Green
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240

9.  Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.

Authors:  Kelley Salem; Michael L McCormick; Erik Wendlandt; Fenghuang Zhan; Apollina Goel
Journal:  Redox Biol       Date:  2014-11-18       Impact factor: 11.799

10.  Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells.

Authors:  Sophie Bustany; Jérôme Bourgeais; Guergana Tchakarska; Simon Body; Olivier Hérault; Fabrice Gouilleux; Brigitte Sola
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.